JNJ241129C205000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Investors in Johnson & Johnson (NYSE:JNJ) Have Seen Decent Returns of 30% Over the Past Five Years
Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share
November 24th (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on November 26th, 2024.Shareholders of record on November 26th, 2024 will receive 1.24 USD dividend per share on
Johnson & Johnson (JNJ.US) has submitted a regulatory application to the FDA for its antibody therapy to treat moderate to severe active ulcerative colitis.
Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biological Product License Application (sBLA) to the FDA in the USA.
Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Express News | Johnson & Johnson is seeking approval from the FDA to use the subcutaneous induction therapy of TREMFYA (GUSELKUMAB) to treat ulcerative colitis.
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis
Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others
Express News | Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya® (Guselkumab) in Ulcerative Colitis, a First for an Il-23 Inhibitor
Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days
Zevra Niemann-Pick Disease Type C Drug Miplyffa Now Available
Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...
Express News | Health Canada Authorizes Carvykti® (Ciltacabtagene Autoleucel) for Patients With Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
Optimism Over Global Healthcare Sector Rises: Jefferies
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Price Over Earnings Overview: Johnson & Johnson
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.